

# Alice Indini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1766419/publications.pdf>

Version: 2024-02-01

78  
papers

1,587  
citations

331670

21  
h-index

361022

35  
g-index

81  
all docs

81  
docs citations

81  
times ranked

2630  
citing authors

#	ARTICLE	IF	CITATIONS
1	BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer. Tumori, 2023, 109, 244-248.	1.1	8
2	Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with ameloblastoma: the experience of 11 Italian centres. Journal of Clinical Pathology, 2022, 75, 555-559.	2.0	8
3	Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib. Clinical Pharmacology: Advances and Applications, 2022, Volume 14, 1-9.	1.2	3
4	Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. ESMO Open, 2022, 7, 100406.	4.5	31
5	Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review. International Journal of Molecular Sciences, 2022, 23, 147.	4.1	8
6	Extended interval dosing in patients with cancer receiving immune checkpoint inhibitors: Safety analysis from the EDICI study.. Journal of Clinical Oncology, 2022, 40, 2595-2595.	1.6	0
7	Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges. Seminars in Cancer Biology, 2022, 86, 477-490.	9.6	10
8	Triage process for the assessment of coronavirus disease 2019â€positive patients with cancer: The ONCOVID prospective study. Cancer, 2021, 127, 1091-1101.	4.1	9
9	Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars. Expert Opinion on Pharmacotherapy, 2021, 22, 857-865.	1.8	1
10	A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday. Melanoma Research, 2021, 31, 190-193.	1.2	2
11	Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC. Expert Review of Anticancer Therapy, 2021, 21, 705-713.	2.4	4
12	Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. International Journal of Molecular Sciences, 2021, 22, 2628.	4.1	21
13	The Appropriateness of Invasive Ventilation in COVID-19 Positive Cancer Patients: Proposal of a New Prognostic Score. Viruses, 2021, 13, 508.	3.3	3
14	Association of Obesity With Survival Outcomes in Patients With Cancer. JAMA Network Open, 2021, 4, e213520.	5.9	197
15	Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review. Cancers, 2021, 13, 1794.	3.7	38
16	Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 4774.	4.1	55
17	Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer. Cancers, 2021, 13, 1663.	3.7	18
18	Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial. Lancet Oncology, The, 2021, 22, 573-575.	10.7	7

#	ARTICLE	IF	CITATIONS
19	Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors. <i>Pharmaceutics</i> , 2021, 13, 653.	4.5	33
20	Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 511-522.	6.7	6
21	Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications. <i>Biomedicines</i> , 2021, 9, 607.	3.2	12
22	Management of patients with cancer during the COVID-19 pandemic: The Italian perspective on the second wave. <i>European Journal of Cancer</i> , 2021, 148, 112-116.	2.8	7
23	Cutaneous melanoma in children and adolescents: The EXPERT/PARTNER diagnostic and therapeutic recommendations. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28992.	1.5	9
24	COVID-19 Vaccination in Patients with Classic Kaposi's Sarcoma. <i>Vaccines</i> , 2021, 9, 632.	4.4	1
25	Cancer Mechanisms and Emerging Therapies. <i>Pharmaceutics</i> , 2021, 13, 1045.	4.5	0
26	Uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2021, 162, 226-234.	1.4	58
27	COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report. <i>Melanoma Research</i> , 2021, 31, 490-493.	1.2	6
28	Metabolic disorders and the risk of cholangiocarcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 999-1007.	3.0	9
29	Factors predicting morbidity in surgically-staged high-risk endometrial cancer patients. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 266, 169-174.	1.1	3
30	Current state of the art and future perspectives with immunotherapy in the management of small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1427-1435.	2.5	13
31	Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies. <i>Radiotherapy and Oncology</i> , 2021, 164, 13-19.	0.6	6
32	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. <i>Frontiers in Oncology</i> , 2020, 10, 1652.	2.8	10
33	Novel treatment strategies for early-stage lung cancer: the oncologist's perspective. <i>Journal of Thoracic Disease</i> , 2020, 12, 3390-3398.	1.4	22
34	Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. , 2020, 8, e001117.		32
35	Letter of response to comments on: Developing a risk assessment score for patients with cancer during COVID-19 pandemic: A war on two fronts. <i>European Journal of Cancer</i> , 2020, 140, 161-162.	2.8	1
36	Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer. <i>Cancers</i> , 2020, 12, 2070.	3.7	7

#	ARTICLE	IF	CITATIONS
37	Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy. <i>Cancers</i> , 2020, 12, 3131.	3.7	13
38	A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic. <i>Cancers</i> , 2020, 12, 2452.	3.7	20
39	Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1229-1236.	2.4	3
40	Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. <i>Cancers</i> , 2020, 12, 1259.	3.7	19
41	Developing a risk assessment score for patients with cancer during the coronavirus disease 2019 pandemic. <i>European Journal of Cancer</i> , 2020, 135, 47-50.	2.8	17
42	Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 931-940.	1.8	7
43	Coronavirus infection and immune system: An insight of COVID-19 in cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103059.	4.4	29
44	Immune related adverse events and response to immunotherapy: Focus on corticosteroids. <i>Lung Cancer</i> , 2020, 145, 225.	2.0	5
45	A case of severe pharyngeal-cervical-brachial syndrome induced by nivolumab and responding to infliximab therapy. <i>European Journal of Cancer</i> , 2020, 129, 1-3.	2.8	3
46	Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey. <i>European Journal of Cancer</i> , 2020, 132, 17-23.	2.8	79
47	Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 998.	3.7	23
48	Advances in laparoscopic surgery for cervical cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 76-80.	4.4	17
49	Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma. <i>Tumori</i> , 2019, 105, 465-473.	1.1	4
50	Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival. <i>Future Oncology</i> , 2019, 15, 967-977.	2.4	10
51	Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 817-827.	6.7	29
52	Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience. <i>Melanoma Research</i> , 2019, 29, 289-294.	1.2	5
53	Artificial Intelligence Estimates the Importance of Baseline Factors in Predicting Response to Anti-PD1 in Metastatic Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 643-648.	1.3	11
54	Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 511-521.	2.5	153

#	ARTICLE	IF	CITATIONS
55	Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e94.	2.2	29
56	Baseline predictive factors for efficacy of anti-PD1 used in first line in melanoma patients: An Italian melanoma intergroup study. <i>Annals of Oncology</i> , 2018, 29, viii449.	1.2	0
57	Hyperprogression during immuno-checkpoint inhibitors (ICIs): A clinically significant problem?. <i>Annals of Oncology</i> , 2018, 29, viii430.	1.2	2
58	Cutaneous melanoma in adolescents and young adults. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27292.	1.5	24
59	Human papillomavirus (HPV) persistence and HPV 31 predict the risk of recurrence in high-grade vaginal intraepithelial neoplasia. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 210, 157-165.	1.1	27
60	Minimally Invasive Surgical Staging in Early-stage Ovarian Carcinoma: A Systematic Review and Meta-analysis. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 552-562.	0.6	46
61	The association of pre-treatment HPV subtypes with recurrence of VIN. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 211, 37-41.	1.1	14
62	Impact of Blood Transfusions on Survival of Locally Advanced Cervical Cancer Patients Undergoing Neoadjuvant Chemotherapy Plus Radical Surgery. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 514-522.	2.5	15
63	Gastrointestinal tract carcinoma in pediatric and adolescent age: The Italian TREP project experience. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26658.	1.5	22
64	Incidental ameloblastoma diagnosed after treatment for childhood tumor. <i>Journal of Pediatric Surgery Case Reports</i> , 2017, 23, 50-52.	0.2	2
65	Long-term safety of growth hormone replacement therapy after childhood medulloblastoma and PNET: it is time to set aside old concerns. <i>Journal of Neuro-Oncology</i> , 2017, 131, 349-357.	2.9	11
66	Minimally Invasive Surgical Staging for Ovarian Carcinoma: A Propensity-Matched Comparison With Traditional Open Surgery. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 98-102.	0.6	32
67	Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 208, 41-45.	1.1	12
68	Surgical Management and Prognostic Factors of Vulvovaginal Melanoma. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, e24-e29.	1.9	33
69	Measuring the efficacy of a project for adolescents and young adults with cancer: A study from the Milan Youth Project. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2197-2204.	1.5	28
70	Morcellation of undiagnosed uterine sarcoma: A critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 302-308.	4.4	27
71	Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio. <i>Journal of Clinical Oncology</i> , 2016, 34, 1017-1018.	1.6	5
72	Surgical Techniques for Diaphragmatic Resection During Cytoreduction in Advanced or Recurrent Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 371-380.	2.5	15

#	ARTICLE	IF	CITATIONS
73	How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. <i>Oncotarget</i> , 2016, 7, 44841-44847.	1.8	15
74	Abstract 3943: Baseline LDH serum level as predictive value of activity in patients treated with anti PD-1 and PDL-1 monoclonal antibodies. , 2016, , .		0
75	Everolimus treatment in advanced solid tumors: a personal view. <i>Future Science OA</i> , 2015, 1, FSO3.	1.9	1
76	Medulloblastoma treatment in a child on dialysis. <i>CNS Oncology</i> , 2014, 3, 31-36.	3.0	0
77	Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience. <i>Child's Nervous System</i> , 2013, 29, 1107-1112.	1.1	14
78	EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation. <i>International Journal of Medical Sciences</i> , 2013, 10, 320-330.	2.5	106